Latest Conference Articles

December 4th 2018, 5:15am

ASH Annual Meeting and Exposition

Axicabtagene ciloleucel elicited a 2-year overall survival rate of 51% in patients with refractory large B cell lymphoma, representing a clear plateau in the survival curve.

December 4th 2018, 4:42am

ASH Annual Meeting and Exposition

The overall survival benefit with quizartinib in patients with relapsed/refractory FLT3-ITD-mutated acute myeloid leukemia was observed across patient subgroups and reproduced consistently across sensitivity analyses.

December 4th 2018, 3:25am

ASH Annual Meeting and Exposition

The first-line combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) was associated with a 77% reduction in the risk for disease progression or death compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

December 4th 2018, 1:02am

ASH Annual Meeting and Exposition

Long-term follow-up of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma shows that responses are durable with no new safety signals observed.

December 3rd 2018, 10:19pm

ASH Annual Meeting and Exposition

The R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) reduced the risk of disease progression or death by 54% versus rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

December 3rd 2018, 9:29pm

ASH Annual Meeting and Exposition

The addition of a CD79b-targeted antibody-drug conjugate to bendamustine and rituximab more than doubled overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma.

December 3rd 2018, 8:41pm

ASH Annual Meeting and Exposition

More than 70% of older patients ineligible for intensive chemotherapy for acute myeloid leukemia had complete responses to venetoclax combined with hypomethylating agents, preliminary results from clinical trials have shown.

December 3rd 2018, 10:10am

ASH Annual Meeting and Exposition

The anti-BCMA CAR T cell therapy bb21217 demonstrated an objective response rate of 83.3%, with a very good partial response or better rate of 75% in patients with heavily pretreated relapsed/refractory multiple myeloma.

December 3rd 2018, 7:19am

ASH Annual Meeting and Exposition

An approach using machine learning to analyze genomic and clinical data from patients with myelodysplastic syndromes could replace the gold standard of predicting how long patients may live with the disease.

December 3rd 2018, 6:43am

ASH Annual Meeting and Exposition

John P. Leonard, MD, associate dean for clinical research and Richard T. Silver Distinguished Professor of Hematology and Medical Oncology, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, discusses the key takeaway from the phase III AUGMENT trial, a randomized study of lenalidomide (Revlimid) plus rituximab (Rituxan) (R2) versus rituximab/placebo in patients with relapsed/refractory indolent non-Hodgkin lymphoma, during the 2018 ASH Annual Meeting.

December 3rd 2018, 6:41am

ASH Annual Meeting and Exposition

Jordan Gauthier, MD, MSc, senior clinical research fellow, Fred Hutchinson Cancer Research Center, discusses a study comparing efficacy and toxicity of CD19-specific chimeric antigen receptor (CAR) T cells alone or in combination with ibrutinib in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) during the 2018 ASH Annual Meeting.

December 3rd 2018, 5:43am

ASH Annual Meeting and Exposition

The CD3 and CD20 bispecific antibody mosunetuzumab demonstrated promising complete remission rates with tolerable toxicity for patients with relapsed/refractory B-cell indolent and aggressive non-Hodgkin lymphoma.

December 3rd 2018, 4:24am

ASH Annual Meeting and Exposition

The triplet regimen of pembrolizumab (Keytruda) plus umbralisib and ublituximab reached a 90% response rate in patients with relapsed/refractory chronic lymphocytic leukemia.

December 3rd 2018, 4:20am

ASH Annual Meeting and Exposition

Initial findings from the Beat AML study showed that rapid genetic testing in patients with AML was feasible and helpful, and that a precision medicine approach is possible for these patients, who must be treated urgently given the disease’s rapid progression.

December 3rd 2018, 4:19am

ASH Annual Meeting and Exposition

Lisocabtagene maraleucel appeared tolerable and induced an 81.3% best overall response rate and 43.8% complete response rate in heavily pretreated, high-risk patients with chronic lymphocytic leukemia who previously received ibrutinib.

December 3rd 2018, 3:33am

ASH Annual Meeting and Exposition

Single-agent ibrutinib continued to demonstrate strong results after 7 years of follow-up in both the frontline and heavily pretreated, relapsed/refractory setting for patients with CLL and SLL.

December 3rd 2018, 2:10am

ASH Annual Meeting and Exposition

Two-year maintenance therapy with ixazomib led to a 39% improvement in progression-free survival compared with placebo in patients with newly diagnosed multiple myeloma who achieved a partial response to induction treatment with a proteasome inhibitor and/or an immunomodulatory agent following autologous stem cell transplant.

December 3rd 2018, 1:30am

ASH Annual Meeting and Exposition

The combination of ibrutinib and venetoclax is well tolerated and eradicates minimal residual disease in the marrow after 12 months in 39% of patients with relapsed/refractory chronic lymphocytic leukemia.

December 2nd 2018, 11:20pm

ASH Annual Meeting and Exposition

The investigational agent zanubrutinib, a next-generation Bruton’s tyrosine kinase inhibitor, is highly active in patients with relapsed/refractory mantle cell lymphoma.

December 2nd 2018, 7:09pm

ASH Annual Meeting and Exposition

Checkpoint inhibition showed promise for augmenting or extending response to chimeric antigen receptor T-cell therapy in some patients with relapsed B-cell acute lymphoblastic leukemia.